All

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
25 September 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...

Read more
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23 September 2020

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read more
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
22 September 2020

Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in...

Read more
The Medical University of Pleven Leads the Digital Transformation of Medical Education in Bulgaria with Lecturio
17 September 2020

The Medical University of Pleven Leads the Digital Transformation of Medical Education in Bulgaria with Lecturio

Already an attractive destination for international and domestic medical students alike, the Medical University of Pleven now joins with Lecturio's help over 100 other medical...

Read more
LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases
9 September 2020

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases

LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that...

Read more
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9 September 2020

Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read more
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
2 September 2020

BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease

As part of the collaboration, BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the aim of identifying biomarkers using the XMarker...

Read more
IDnow acquires Wirecard Communication Services
1 September 2020

IDnow acquires Wirecard Communication Services

IDnow, a leading provider of Identity Verification-as-a-Service solutions and Wirecard Communication Services GmbH announce the signing of an agreement for the acquisition of...

Read more
IZICAP JOINS MASTERCARD START PATH STARTUP ENGAGEMENT PROGRAM
27 August 2020

IZICAP JOINS MASTERCARD START PATH STARTUP ENGAGEMENT PROGRAM

IZICAP, the European leader of card-linked CRM & Loyalty platform dedicated to local merchants, is supported by Mastercard in its scaling strategy.

Read more

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse